IJCS | Volume 31, Nº6, November / December 2018

661 in a patient with hyper-immunoglobulin E-emia. Am J Case Rep. 2016 Apr 11;17:235-40. 47. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1(2):e000364. 48. Ton VK, Mukherjee M, Judge DP. Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role inheart failurewithpreserved ejection fraction. Clin Med Insights Cardiol. 2015;8(Suppl 1):39-44. 49. Bicca J, Jarske LP, Silva TO, Gismondi R, Mocarzel LO, Lanzieri PG. Cirrhotic Cardiomyopathy. Int J Cardiovasc Sci. 2016;29(2):139-48. Mesquita et al. HFPEF phenotypes Int J Cardiovasc Sci. 2018;31(6)652-661 Review Article This is an open-access article distributed under the terms of the Creative Commons Attribution License